Madhav V. Dhodapkar MBBS

Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology; Chief, Section of Hematology, Department of Internal Medicine; Clinical Research Program Leader, Hematology Program, Yale Cancer Center

Departments & Organizations

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Immunology | Molecular Medicine, Pharmacology, and Physiology

Yale Medical Group

Office of Student ResearchCancer Center, Yale: Hematology Program; Cancer Immunology; Dhodapkar LabImmunobiology: HTIHematology | National Gaucher Disease Treatment Center

Research Interests

Myeloma and related plasma cell disorders; Human immune system's interaction with growing tumors in patients; Preneoplastic monoclonal gammopathy and multiple myeloma, tumor and host related factors more...


  • M.B.B.S., All India Institute of Medical Sciences, New Delhi, 1987

Selected Publications

  • Dhodapkar K, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM, Dhodapkar MV. Selective blockade of the inhibitory FC-receptor (Fc-RIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med. 2007, 204: 1359-1369.
  • Spisek R, Kukreja A, Chen L, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJG, Ritter G, Durie B, Crowley J, Shaughnessy Jr. JD, Scanlan M, Gure AO, Barlogie B, Dhodapkar MV. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med. 2007, 204: 831-840.
  • Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath, Dhodapkar MV. Bortezomib enhances dendritic cell mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood. 2007, 109: 4839-4845.



Latest News


Edit Profile